JR. Strawn, PE. Keck, SN. Caroff. Neuroleptic malignant syndrome. „American Journal of Psychiatry”. 164 (6), s. 870-876, 2007. DOI: 10.1176/appi.ajp.164.6.870. PMID: 17541044.
DP. Seitz, SS. Gill. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. „Psychosomatics”. 50 (1). s. 8-15. DOI: 10.1176/appi.psy.50.1.8. PMID: 19213967.
A. Kogoj, I. Velikonja. Olanzapine induced neuroleptic malignant syndrome--a case review. „Hum Psychopharmacol”. 18 (4), s. 301-309, 2003. DOI: 10.1002/hup.483. PMID: 12766935.
EJ. Newman, DG. Grosset, PG. Kennedy. The parkinsonism-hyperpyrexia syndrome. „Neurocrit Care”. 10 (1), s. 136-40, 2009. DOI: 10.1007/s12028-008-9125-4. PMID: 18712508.
AM Haddow, D Harris, M Wilson, H Logie. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. „BMJ”. 329 (7478), s. 1333-1335, 2004. DOI: 10.1136/bmj.329.7478.1333. PMID: 15576745.
JA. Boulant. Role of the preoptic-anterior hypothalamus in thermoregulation and fever.. „Clin Infect Dis”. 31 Suppl 5, s. S157-61, 2000. DOI: 10.1086/317521. PMID: 11113018.
K Otani, M Horiuchi, T Kondo, S Kaneko i inni. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. „Br J Psychiatry”. 158, s. 850-853, 1991. DOI: 10.1192/bjp.158.6.850. PMID: 1678666.
K Mihara, T Kondo, A Suzuki, N. Yasui-Furukori i inni. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. „Am J Med Genet B Neuropsychiatr Genet”. 117B (1), s. 57-60, 2003. DOI: 10.1002/ajmg.b.10025. PMID: 12555236.
Adityanjee. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. „Br J Psychiatry”. 158, s. 706-707, 1991. DOI: 10.1192/bjp.158.5.706. PMID: 1677602.
RJ. Gurrera, SN. Caroff, A. Cohen, BT. Carroll i inni. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.. „J Clin Psychiatry”. 72 (9), s. 1222-1228, 2011. DOI: 10.4088/JCP.10m06438. PMID: 21733489.
Y. Tsutsumi, K. Yamamoto, S. Matsuura, S. Hata i inni. The treatment of neuroleptic malignant syndrome using dantrolene sodium.. „Psychiatry Clin Neurosci”. 52 (4), s. 433-8, Aug 1998. DOI: 10.1046/j.1440-1819.1998.00416.x. PMID: 9766694.
MJ. Bhanushali, PJ. Tuite. The evaluation and management of patients with neuroleptic malignant syndrome.. „Neurol Clin”. 22 (2), s. 389-411, 2004. DOI: 10.1016/j.ncl.2003.12.006. PMID: 15062519.
U Tural, E Onder. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death.. „Psychiatry Clin Neurosci”. 64 (1), s. 79-87, 2010. DOI: 10.1111/j.1440-1819.2009.02042.x. PMID: 20416027.
M Nakamura, H Yasunaga, H Miyata, T Shimada i inni. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. „J Clin Psychiatry”. 73 (4), s. 427-430, 2012. DOI: 10.4088/JCP.10m06791. PMID: 22154901.
VR. Velamoor. Neuroleptic malignant syndrome. Recognition, prevention and management.. „Drug Saf”. 19 (1), s. 73-82, Jul 1998. PMID: 9673859.
PE. Keck, HG. Pope, BM. Cohen, SL. McElroy i inni. Risk factors for neuroleptic malignant syndrome. A case-control study. „Arch Gen Psychiatry”. 46 (10), s. 914-918, 1989. PMID: 2572206.
JR. Strawn, PE. Keck, SN. Caroff. Neuroleptic malignant syndrome. „American Journal of Psychiatry”. 164 (6), s. 870-876, 2007. DOI: 10.1176/appi.ajp.164.6.870. PMID: 17541044.
DP. Seitz, SS. Gill. Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature. „Psychosomatics”. 50 (1). s. 8-15. DOI: 10.1176/appi.psy.50.1.8. PMID: 19213967.
A. Kogoj, I. Velikonja. Olanzapine induced neuroleptic malignant syndrome--a case review. „Hum Psychopharmacol”. 18 (4), s. 301-309, 2003. DOI: 10.1002/hup.483. PMID: 12766935.
HG. Pope, HG. Aizley, PE. Keck, SL. McElroy. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. „J Clin Psychiatry”. 52 (5), s. 208-212, 1991. PMID: 1674508.
H. Hermesh, D. Aizenberg, A. Weizman, M. Lapidot i inni. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. „Br J Psychiatry”. 161, s. 254-257, 1992. PMID: 1355693.
D. Berardi, M. Amore, PE. Keck, M. Troia i inni. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study.. „Biol Psychiatry”. 44 (8), s. 748-754, 1998. PMID: 9798079.
Y. Mizuno, H. Takubo, E. Mizuta, S. Kuno. Malignant syndrome in Parkinson's disease: concept and review of the literature. „Parkinsonism Relat Disord”. 9 Suppl 1, s. S3-9, Apr 2003. PMID: 12735909.
M. Serrano-Dueñas. Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. „Parkinsonism Relat Disord”. 9 (3), s. 175-178, 2003. PMID: 12573874.
GP. Sechi, F. Tanda, R. Mutani. Fatal hyperpyrexia after withdrawal of levodopa.. „Neurology”. 34 (2), s. 249-251, 1984. PMID: 6538021.
EJ. Newman, DG. Grosset, PG. Kennedy. The parkinsonism-hyperpyrexia syndrome. „Neurocrit Care”. 10 (1), s. 136-40, 2009. DOI: 10.1007/s12028-008-9125-4. PMID: 18712508.
M Koch, S Chandragiri, S Rizvi, G Petrides i inni. Catatonic signs in neuroleptic malignant syndrome. „Compr Psychiatry”. 41 (1). s. 73-75. PMID: 10646623.
P Adnet, P Lestavel, R Krivosic-Horber. Neuroleptic malignant syndrome.. „Br J Anaesth”. 85 (1), s. 129-135, 2000. PMID: 10928001.
AM Haddow, D Harris, M Wilson, H Logie. Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin. „BMJ”. 329 (7478), s. 1333-1335, 2004. DOI: 10.1136/bmj.329.7478.1333. PMID: 15576745.
P. Rosebush, T. Stewart. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. „Am J Psychiatry”. 146 (6), s. 717-725, 1989. PMID: 2567121.
H. Tanii, N Taniguchi, H Niigawa, T Hosono i inni. Development of an animal model for neuroleptic malignant syndrome: heat-exposed rabbits with haloperidol and atropine administration exhibit increased muscle activity, hyperthermia, and high serum creatine phosphokinase level. „Brain Res”. 743 (1-2), s. 263-270, 1996. PMID: 9017254.
SN Caroff, SC Mann, PE Keck. Specific treatment of the neuroleptic malignant syndrome. „Biol Psychiatry”. 44 (6), s. 378-381, 1998. PMID: 9777166.
JA. Boulant. Role of the preoptic-anterior hypothalamus in thermoregulation and fever.. „Clin Infect Dis”. 31 Suppl 5, s. S157-61, 2000. DOI: 10.1086/317521. PMID: 11113018.
VW Henderson, GF Wooten. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?. „Neurology”. 31 (2), s. 132-137, 1981. PMID: 6110195.
B Spivak, DI Maline, Y Vered, VN Kozyrev i inni. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. „Acta Psychiatr Scand”. 102 (3), s. 226-230, 2000. PMID: 11008859.
RJ. Gurrera. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?. „Clin Neuropharmacol”. 25 (4). s. 183-93. PMID: 12151905.
K Otani, M Horiuchi, T Kondo, S Kaneko i inni. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?. „Br J Psychiatry”. 158, s. 850-853, 1991. DOI: 10.1192/bjp.158.6.850. PMID: 1678666.
K Mihara, T Kondo, A Suzuki, N. Yasui-Furukori i inni. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. „Am J Med Genet B Neuropsychiatr Genet”. 117B (1), s. 57-60, 2003. DOI: 10.1002/ajmg.b.10025. PMID: 12555236.
VR Velamoor, RM Norman, SN Caroff, SC Mann i inni. Progression of symptoms in neuroleptic malignant syndrome. „J Nerv Ment Dis”. 182 (3), s. 168-173, 1994. PMID: 7906709.
Adityanjee. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. „Br J Psychiatry”. 158, s. 706-707, 1991. DOI: 10.1192/bjp.158.5.706. PMID: 1677602.
H. Hermesh, I. Manor, R. Shiloh, D. Aizenberg i inni. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. „J Clin Psychopharmacol”. 22 (3), s. 252-6, Jun 2002. PMID: 12006894.
AR Eiser, MS Neff, RF Slifkin. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. „Arch Intern Med”. 142 (3), s. 601-603, 1982. PMID: 6121542.
SN. Caroff, H. Rosenberg, JE. Fletcher, TD. Heiman-Patterson i inni. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. „Anesthesiology”. 67 (1), s. 20-25, 1987. PMID: 3605730.
RJ. Gurrera, SN. Caroff, A. Cohen, BT. Carroll i inni. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.. „J Clin Psychiatry”. 72 (9), s. 1222-1228, 2011. DOI: 10.4088/JCP.10m06438. PMID: 21733489.
AK Parry, LP Ormerod, GW Hamlin, PT Saleem. Recurrent sinus arrest in association with neuroleptic malignant syndrome. „Br J Psychiatry”. 164 (5), s. 689-691, 1994. PMID: 7921725.
Prevention and treatment of heat injury.. „Med Lett Drugs Ther”. 45 (1161), s. 58-60, 2003. PMID: 12865866.
Y. Tsutsumi, K. Yamamoto, S. Matsuura, S. Hata i inni. The treatment of neuroleptic malignant syndrome using dantrolene sodium.. „Psychiatry Clin Neurosci”. 52 (4), s. 433-8, Aug 1998. DOI: 10.1046/j.1440-1819.1998.00416.x. PMID: 9766694.
MJ. Bhanushali, PJ. Tuite. The evaluation and management of patients with neuroleptic malignant syndrome.. „Neurol Clin”. 22 (2), s. 389-411, 2004. DOI: 10.1016/j.ncl.2003.12.006. PMID: 15062519.
P Sakkas, JM Davis, PG Janicak, ZY Wang. Drug treatment of the neuroleptic malignant syndrome. „Psychopharmacol Bull”. 27 (3), s. 381-4, 1991. PMID: 1685592.
PI Rosebush, T Stewart, MF Mazurek. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?. „Br J Psychiatry”. 159, s. 709-712, 1991. PMID: 1843801.
JM Davis, PG Janicak, P Sakkas, C Gilmore i inni. Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome. „Convuls Ther”. 7 (2), s. 111-120, 1991. PMID: 11941110.
JN Trollor, PS Sachdev. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. „Aust N Z J Psychiatry”. 33 (5), s. 650-659, 1999. PMID: 10544988.
SN Caroff, SC Mann, PE Keck, A Francis. Residual catatonic state following neuroleptic malignant syndrome. „J Clin Psychopharmacol”. 20 (2), s. 257-259, 2000. PMID: 10770467.
U Tural, E Onder. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death.. „Psychiatry Clin Neurosci”. 64 (1), s. 79-87, 2010. DOI: 10.1111/j.1440-1819.2009.02042.x. PMID: 20416027.
M Nakamura, H Yasunaga, H Miyata, T Shimada i inni. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. „J Clin Psychiatry”. 73 (4), s. 427-430, 2012. DOI: 10.4088/JCP.10m06791. PMID: 22154901.